Search results for " titers"
Article
Fusion Proteins Pose Manufacturability Challenges
The titers for fusion proteins are generally lower than those for mAbs due to less efficient translation, notes Chamow.
Non-human glycans—such as N-glycolylneuraminic acid and alpha-galactose—are …
Article
Evolution of the Monoclonal Antibody Purification Platform
For a given amount of mAb product manufactured, the ATPS-based process reduced the annual operating cost by 40% when cell-culture supernatants with mAb titers higher than 2.5 g/L are processed.
…
Article
Digitalization: The Route to Biopharma 4.0
Industry 4.0, also known as the Fourth Industrial Revolution (4IR), will result in the digital transformation of the manufacturing sector. It is propelled by transformative trends such as the prolif…
Article
Simple Fed-Batch Process Development for a Knockout Cell Line
CLICK HERE TO READ MORE >>
This workflow improved titers by 500% compared with Chinese hamster ovary cell culture in basal medium.
Article
Updating Viral Clearance for New Biologic Modalities
Viral clearance processes and guidance must evolve along with newer biotherapeutic modalities.
By Feliza Mirasol
Ensuring viral clearance (i.e., removal) in downstream purification has becom…
Article
Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow
The increase in titers and the trend toward continuous biomanufacturing will lead to increased demand in buffer volumes and prep times. To address this gap, strategies for improving mAb manufacturing …
Article
Improving Upstream Predictability
“We’ve consistently been seeing titers in the range of 4–6 g/L in [monoclonal antibody] mAb fed-batch processing within a chemically defined media environment. This environment, in turn, results in mo…
Article
Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation
By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioproc…
Article
Mapping a Route for Cell and Gene Therapy Process Development
While cell and gene therapies differ in many ways, some of the best practices for process development and validation are similar.
By Cynthia A. Challener
…
Article
Best Practices for Selecting a Top-Quality Cell Line
Irina Shi - Stock.Adobe.com
Leveraging automation and a step-by-step approach are keys to success.
By Cynthia A. Challener
Cell lines determine the performanc…